1
|
Saydam M, Timur SS, Vural İ, Takka S. Cell culture and pharmacokinetic evaluation of a solid dosage formulation containing a water-insoluble orphan drug manufactured by FDM-3DP technology. Int J Pharm 2022; 628:122307. [DOI: 10.1016/j.ijpharm.2022.122307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 10/11/2022] [Accepted: 10/12/2022] [Indexed: 11/28/2022]
|
2
|
Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study. Support Care Cancer 2022; 30:8845-8853. [PMID: 35953729 DOI: 10.1007/s00520-022-07317-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 08/02/2022] [Indexed: 01/05/2023]
Abstract
Chemotherapy-induced neuropathy is difficult to manage, and the pain associated with neuropathy is poorly responsive to gabapentin in a randomized trial. Duloxetine is the only drug that has been found to be effective in reducing pain from chemotherapy neuropathy. In this qualitative review, the use of pregabalin for chemotherapy-induced neuropathy is discussed including the rationale and pharmacological reasons why pregabalin should be considered in a large, randomized placebo-controlled trial.
Collapse
|
3
|
Potměšil P, Kostýlková L, Kopeček M. Increased amisulpride serum concentration in a patient treated with concomitant pregabalin and trazodone: a case report. Ther Adv Psychopharmacol 2022; 12:20451253221136754. [PMID: 36465957 PMCID: PMC9716442 DOI: 10.1177/20451253221136754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 10/12/2022] [Indexed: 12/02/2022] Open
Abstract
We report on the case of a 46-year-old woman with generalized anxiety disorder, paranoid personality disorder, and mild reduction in glomerular filtration rate (GFR). She was treated with pregabalin, trazodone, hydroxyzine, and clonazepam before hospital admission. Pharmacotherapy for the patient was changed during her first week in the hospital. Dosing of hydroxyzine and clonazepam was gradually decreased, and then these two drugs were withdrawn. Treatment with amisulpride was started on the fourth day after admission, and amisulpride serum levels were then measured three times as a part of therapeutic drug monitoring (TDM). The serum concentration of amisulpride detected during concurrent use of trazodone and pregabalin was approximately twice the therapeutic range for amisulpride. When the dose of pregabalin was reduced by half, the serum concentration of amisulpride decreased to therapeutic serum levels. We hypothesize that an interaction between amisulpride and pregabalin was responsible for the increased amisulpride concentration since both drugs are almost exclusively excreted from the body by the renal route. Pregabalin-amisulpride interaction might also be influenced by concomitant therapy with trazodone or a mild reduction in GFR. However, we only have clinical evidence for an interaction between amisulpride and pregabalin because after we halved the dose of pregabalin, the amisulpride concentration decreased, and the C/D ratio normalized. This could be helpful information for psychiatrists in order to avoid drug-drug interactions between amisulpride and pregabalin. We recommend TDM of amisulpride in patients treated concomitantly with other drugs eliminated mainly by the kidneys.
Collapse
Affiliation(s)
- Petr Potměšil
- Department of Pharmacology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Lenka Kostýlková
- National Institute of Mental Health, Klecany, Czech Republic; Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Miloslav Kopeček
- National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic.,Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
4
|
Yu H, He B, Han X, Yan T. Rufinamide (RUF) suppresses inflammation and maintains the integrity of the blood-brain barrier during kainic acid-induced brain damage. Open Life Sci 2021; 16:845-855. [PMID: 34514163 PMCID: PMC8389504 DOI: 10.1515/biol-2021-0090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Revised: 07/14/2021] [Accepted: 07/16/2021] [Indexed: 11/15/2022] Open
Abstract
Rufinamide (RUF) is a structurally unique anti-epileptic drug, but its protective mechanism against brain injury remains unclear. In the present study, we validated how the RUF protected mice with kainic acid (KA)-induced neuronal damage. To achieve that, a mouse epilepsy model was established by KA intraperitoneal injection. After Nissl staining, although there was a significant reduction in Nissl bodies in mice treated with KA, 40, 80, and 120 mg/kg, RUF significantly reduced KA-induced neuronal damage, in a dose-dependent manner. Among them, 120 mg/kg RUF was most pronounced. Immunohistochemistry (IHC) and western blot analysis showed that RUF inhibited the IBA-1 overexpression caused by KA to block microglia cell overactivation. Further, RUF treatment partially reversed neuroinflammatory cytokine (IL-1β, TNFα, HMGB1, and NLRP3) overexpression in mRNA and protein levels in KA mice. Moreover, although KA stimulation inhibited the expression of tight junctions, RUF treatment significantly upregulated expression of tight junction proteins (occludin and claudin 5) in both mRNA and protein levels in the brain tissues of KA mice. RUF inhibited the overactivation of microglia, suppressed the neuroinflammatory response, and reduced the destruction of blood-brain barrier, thereby alleviating the excitatory nerve damage of the KA-mice.
Collapse
Affiliation(s)
- Huaxu Yu
- General Surgery Department, Changsha Hospital of Hunan Normal University, No. 70, Lushan Road, Changsha 410000, Hunan, China
| | - Bin He
- General Surgery Department, Changsha Hospital of Hunan Normal University, No. 70, Lushan Road, Changsha 410000, Hunan, China
| | - Xu Han
- General Surgery Department, Changsha Hospital of Hunan Normal University, No. 70, Lushan Road, Changsha 410000, Hunan, China
| | - Ting Yan
- Department of Clinical Skills Training Center of ZhuJiang Hospital, ZhuJiang Hospital of Southern Medical University, Guangzhou 510282, China
| |
Collapse
|
5
|
Fei Z, Hu M, Baum L, Kwan P, Hong T, Zhang C. The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro. Xenobiotica 2019; 50:354-362. [PMID: 31132291 DOI: 10.1080/00498254.2019.1623935] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Ziyan Fei
- School of Pharmacy, Nanchang University, Nanchang, PR China
- Provincial Key Laboratory for Drug Targeting and Drug Screening Research, Nanchang, PR China
| | - Mengyun Hu
- School of Pharmacy, Nanchang University, Nanchang, PR China
- Provincial Key Laboratory for Drug Targeting and Drug Screening Research, Nanchang, PR China
| | - Larry Baum
- The State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Pokfulam, Hong Kong, PR China
- Centre for Genomic Sciences, University of Hong Kong, Pokfulam, Hong Kong, PR China
| | - Patrick Kwan
- Department of Neuroscience, Alfred Hospital, Monash University, Melbourne, Australia
- Departments of Medicine and Neurology, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia
| | - Tao Hong
- Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, PR China
| | - Chunbo Zhang
- School of Pharmacy, Nanchang University, Nanchang, PR China
- Provincial Key Laboratory for Drug Targeting and Drug Screening Research, Nanchang, PR China
| |
Collapse
|
6
|
Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Epilepsy Res 2016; 121:1-7. [DOI: 10.1016/j.eplepsyres.2016.01.002] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2015] [Revised: 11/29/2015] [Accepted: 01/10/2016] [Indexed: 10/22/2022]
|
7
|
The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2). Neuropharmacology 2015; 93:7-14. [DOI: 10.1016/j.neuropharm.2015.01.015] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Revised: 01/14/2015] [Accepted: 01/16/2015] [Indexed: 01/16/2023]
|
8
|
Jokinen V, Lilius T, Laitila J, Niemi M, Rauhala P, Kalso E. Pregabalin enhances the antinociceptive effect of oxycodone and morphine in thermal models of nociception in the rat without any pharmacokinetic interactions. Eur J Pain 2015; 20:297-306. [DOI: 10.1002/ejp.728] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/25/2015] [Indexed: 12/26/2022]
Affiliation(s)
- V. Jokinen
- Department of Pharmacology; Faculty of Medicine; University of Helsinki; Finland
| | - T.O. Lilius
- Department of Pharmacology; Faculty of Medicine; University of Helsinki; Finland
| | - J. Laitila
- Department of Clinical Pharmacology; Faculty of Medicine; University of Helsinki; Finland
| | - M. Niemi
- Department of Clinical Pharmacology; Faculty of Medicine; University of Helsinki; Finland
- HUSLAB; Helsinki University Central Hospital; Finland
| | - P.V. Rauhala
- Department of Pharmacology; Faculty of Medicine; University of Helsinki; Finland
| | - E.A. Kalso
- Department of Pharmacology; Faculty of Medicine; University of Helsinki; Finland
- Department of Anaesthesia and Intensive Care Medicine; Pain Clinic; Helsinki University Central Hospital; Finland
| |
Collapse
|
9
|
Gáll Z, Vancea S, Szilágyi T, Gáll O, Kolcsár M. Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats. Eur J Pharm Sci 2014; 68:106-13. [PMID: 25530452 DOI: 10.1016/j.ejps.2014.12.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Revised: 11/07/2014] [Accepted: 12/13/2014] [Indexed: 11/30/2022]
Abstract
Rufinamide is a third-generation antiepileptic drug, approved recently as an orphan drug for the treatment of Lennox-Gastaut syndrome. Although extensive research was conducted, its pharmacokinetics in rats was not described. This work addresses that area by describing in a rapid pharmacokinetic study the main pharmacokinetic properties of rufinamide at three different doses of 1 mg/kg body weight (bw), 5 mg/kg bw, and 20 mg/kg bw. Furthermore, total brain concentrations of the drug were determined in order to characterize its brain-to-plasma partition coefficient. Adult Wistar male rats, weighing 200-450 g, were administered rufinamide by intravenous and oral routes. Rufinamide concentrations from plasma samples and brain tissue homogenate were determined using a liquid chromatography-mass spectrometric method and pharmacokinetic parameters were calculated. The mean half-life was between 7 and 13 h, depending on route of administration--intravenously administered drug was eliminated faster than orally administered drug. Mean (S.E.M.) total plasma clearance was 84.01 ± 3.80 ml/h/kg for intravenous administration, while the apparent plasma clearance for oral administration was 95.52 ± 39.45 ml/h/kg. The mean (S.E.M.) maximum plasma concentration reached after oral administration of 1 mg/kg bw and 5 mg/kg bw was 0.89 ± 0.09 μg/ml and 3.188 ± 0.71 μg/ml, respectively. The median (range) time to reach maximum plasma concentration (t(max)) was 4 (2-8)h. Mean (S.E.M.) brain-to-plasma concentration ratio of rufinamide was 0.514 ± 0.036, consistent with the brain-to-plasma ratio calculated from the area under curves (AUC(0-t)) of 0.441 ± 0.047. No influence of dose, route of administration, or post-dosing time was observed on brain-to-plasma ratio.
Collapse
Affiliation(s)
- Zsolt Gáll
- University of Medicine and Pharmacy of Tirgu Mures, Faculty of Medicine, Department of Physiology, Doctoral School, Romania; University of Medicine and Pharmacy of Tirgu Mures, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Romania
| | - Szende Vancea
- University of Medicine and Pharmacy of Tirgu Mures, Faculty of Pharmacy, Department of Physical Chemistry, Romania.
| | - Tibor Szilágyi
- University of Medicine and Pharmacy of Tirgu Mures, Faculty of Medicine, Department of Physiology, Doctoral School, Romania; University of Medicine and Pharmacy of Tirgu Mures, Faculty of Medicine, Department of Physiology, Romania
| | - Orsolya Gáll
- University of Medicine and Pharmacy of Tirgu Mures, Faculty of Medicine, Department of Physiology, Romania
| | - Melinda Kolcsár
- University of Medicine and Pharmacy of Tirgu Mures, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Romania
| |
Collapse
|